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Maintaining physiologic iron concentrations in tissues is critical for metabolism and host defense. Iron ab-
sorption in the duodenum, recycling of iron from senescent erythrocytes, and iron mobilization from storage
in macrophages and hepatocytes constitute the major iron flows into plasma for distribution to tissues, pre-
dominantly for erythropoiesis. All iron transfer to plasma occurs through the iron exporter ferroportin. The
concentration of functional membrane-associated ferroportin is controlled by its ligand, the iron-regulatory
hormone hepcidin, and fine-tuned by regulatory mechanisms serving iron homeostasis, oxygen utilization,
host defense, and erythropoiesis. Fundamental questions about the structure and biology of ferroportin
remain to be answered.Introduction
A major destination for iron in the body is the heme of hemoglo-
bin in red blood cells. Humans normally complete the synthesis
of at least 2 million erythrocytes per second; each mature red
blood cell contains about 280 million molecules of hemoglobin,
and each of the four globin subunits contains one iron atom in
heme, so that the total iron flux required to maintain erythropoi-
esis is about 2–33 1015 atoms of iron per second in an adult hu-
man. The erythropoietic use of iron governs the lion’s share of
iron trafficking, but iron is also required for mitochondrial func-
tion, DNA synthesis, and other basic activities in all cells in the
body; and in pregnancy the growing fetus places a further large
demand on the maternal iron transport system. In humans,
>90% of iron demand (or about 20–25 mg/day) is met by recy-
cling existing iron, with uptake of ‘‘new’’ iron from the diet ac-
counting for about 1 mg of iron per day. Macrophages in the
red pulp of the spleen specialize in the uptake and digestion of
senescent red blood cells, can liberate the iron from heme via
the enzyme heme-oxygenase-1, and release iron back into
plasma. Dietary iron uptake is mediated by duodenal entero-
cytes that capture iron from the diet at their apical surface via
the ferric reductase DcytB and the importer DMT1 and export
iron into plasma through their basolateral membranes (Macken-
zie and Garrick, 2005). Dietary heme represents an important
source of iron, especially in meat eaters, but the mechanism of
its absorption is not yet understood, and it is not known to
what extent heme is converted to inorganic iron within entero-
cytes or transferred intact to plasma. Iron transfer from duodenal
enterocytes to plasma (referred to as ‘‘mucosal transfer’’ in older
literature on intestinal iron absorption) has long been known to
be subject to regulation by systemic influences including iron
deficiency, anemia, and hypoxia (Finch, 1994). How iron entered
plasma from either recycling macrophages or absorptive enter-
ocytes was unknown until the year 2000, when it became
apparent that despite arising from distinct lineages, and despite
their sources of iron being very different, both macrophages and
enterocytes use the same protein to mediate iron export: ferro-
portin (SLC40A1, also referred to in the literature as FPN1,MTP1, and IREG1). Moreover, ferroportin is also used to export
stored iron from hepatocytes and to release maternal iron from
the placenta to the fetal circulation. Three groups (Abboud and
Haile, 2000; Donovan et al., 2000; McKie et al., 2000) indepen-
dently discovered that ferroportin, a multitransmembrane pro-
tein that is well conserved in mammals, appears to be ancient,
with orthologs present in plants and worms, and intriguingly is
not closely related to any other known mammalian transporter
proteins (although there may be some distant homology to bac-
terial transport proteins).
Function and Importance in Physiology
Early work confirmed that ferroportin is highly expressed by
cells and tissues associated with iron transport: duodenal enter-
ocytes, liver Kupffer cells and splenic red pulp macrophages,
periportal hepatocytes, and the placental syncytiotrophoblast
(Figure 1). The ability of ferroportin to mediate iron export was
shown using radioactive iron isotopes in Xenopus laevis oocytes
injected with ferroportin cRNA and human cell lines transfected
with ferroportin-expressing constructs (Donovan et al., 2000;
McKie et al., 2000).
The key role of ferroportin in iron export in vivowas established
using a series of transgenic mice (Donovan et al., 2005). Global
Fpnnull/null mice do not complete embryonic development, likely
because ferroportin is required for transfer of iron to the embryo
through epithelial cells of the extraembryonic visceral endoderm
(exVE). When ferroportin was deleted only in embryo proper but
spared in exVE and placenta, mice survived to birth but rapidly
became anemic and runted after birth and showed marked
iron accumulation in enterocytes, splenic macrophages, and
Kupffer cells, and in hepatocytes. Adult mice in which ferroportin
was inducibly and exclusively deleted in intestinal cells also
rapidly became anemic, demonstrating that ferroportin is essen-
tial for intestinal absorption of iron. Further work inactivating fer-
roportin in macrophages and in hepatocytes showed that ferro-
portin is required in these cells for efficient mobilization of stored
iron; mice lacking ferroportin in these sites become anemic more
rapidly than controls when fed iron-deficient diets (Zhang et al.,Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 777
Figure 1. Systemic Flows of Elemental Iron
The release of iron into blood plasma is mediated by the iron transporter fer-
roportin, which also serves as the control point for the regulation of iron flows.
In plasma, iron is carried by transferrin (Tf-Fe). Red blood cells (RBCs) contain
the majority of the body iron, and iron fluxes in humans are dominated by the
utilization of iron by erythroblasts in the marrow and recycling of iron from the
hemoglobin of senescent erythrocytes by erythrophagocytosing macro-
phages (iMF, iron-recycling macrophages, mostly in the spleen). Other cells in
the body utilize smaller amounts of iron, and this too is recycled by macro-
phages after cells die. The liver is the major storage organ for iron from which
iron can be mobilized in times of need, and where it is deposited when there is
a surplus of iron in the body. Duodenal absorption of iron is the sole external
source of iron, and compensates for the losses of iron from the body which are
normally relatively small. In pregnant women, iron is transferred to fetal blood
through ferroportin in the placenta.
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diet maintained intact erythropoiesis, indicating that duodenal
ferroportin upregulation and increased intestinal absorption
can compensate for the decreased activity of ferroportin in re-
cycling and storage compartments, especially in mice, which
compared to humans derive a larger proportion of their iron flows
from intestinal absorption. Overall, it appears that ferroportin is
the only way elemental iron can exit cells to enter plasma.
Multilevel Regulation of Ferroportin
The regulation of ferroportin expression is complex, with impor-
tant layers of control at transcriptional, posttranscriptional, post-
translational, and cell-lineage levels. These different phases of
control allow multiple and diverse physiological inputs to influ-
ence ferroportin activity at its various sites of expression.
Notably, ferroportin regulation varies among different cell types,
allowing added flexibility in controlling systemic iron flow under
different conditions (Figure 2).
As noted above, macrophages are critical to iron homeostasis
because they take up senescent red blood cells (by a process
referred to as erythrophagocytosis), liberate heme from hemo-
globin, liberate iron from heme, and release iron back into
plasma via ferroportin. Although the overall rate of iron release
is subject to systemic control, the cellular response to erythro-
phagocytosis is cell-autonomously regulated: in the terminal
step of this coordinated sequence, ferroportin expression in
macrophages is increased by heme and iron released from di-
gested erythrocytes (Delaby et al., 2008). Ferroportin contains778 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.in its promoter sequence an antioxidant response element
(ARE) 7 kb upstream of the transcription start site (Marro et al.,
2010); AREs can be bound either by Bach1 (leading to gene
repression) or Nrf2 (leading to gene activation). Heme causes
Bach1 degradation, which may allow Nrf2 to facilitate transcrip-
tional activation of ferroportin (with a similar effect on heme
oxygenase and ferritin, in a coordinated cellular response). Phar-
macological activators of Nrf2 increase Fpn1 mRNA in macro-
phages in an Nrf2-dependent manner, and can counteract the
inflammation-induced suppression of Fpn1 mRNA caused by
LPS (Harada et al., 2011). Iron itself also enhances ferroportin
expression at the translational level. Ferroportin mRNA (isoform
1a, which is abundant in macrophages) contains a 50 iron
response element (IRE), which under conditions of iron defi-
ciency binds IRP proteins, causing translational repression
(Lymboussaki et al., 2003). In erythrophagocytosing macro-
phages, iron liberated from heme by heme oxygenase-1 (that
is also activated by Nrf2) inactivates IRPs, resulting in derepres-
sion of Fpn1a mRNA translation. Moreover, the 30 untranslated
region of ferroportin is targeted by miR-485-3p microRNA which
is induced by cellular iron deficiency (Sangokoya et al., 2013). As
cellular iron levels rise, the downregulation of this miRNA may
also contribute to increased ferroportin expression. The sequen-
tial heme- and iron-mediated induction of ferroportin expression
facilitates efficient recycling or iron from macrophages that have
internalized and degraded senescent erythrocytes (Delaby et al.,
2008; Marro et al., 2010) (Figure 2A).
In duodenal enterocytes, ferroportin production is strongly
regulated by iron and hypoxia, all geared toward increasing
absorption of dietary iron during iron deficiency and anemia
(Figure 2B). The molecular basis for these effects is becoming
clearer. Hypoxia acts by stabilization of hypoxia-inducible fac-
tors (HIFs) that transcriptionally activate genes in order to
respond to a low cellular oxygen state. Iron deficiency also
stabilizes HIFs because their degradation is triggered by iron-
dependent hydroxylation of proline residues, and therefore
HIFs may also function as sensors of iron scarcity. HIF activation
in enterocytes was shown to result in the upregulation of both the
apical iron import machinery, DcytB and DMT1 (Shah et al.,
2009), and the basolateral iron exporter ferroportin (Taylor
et al., 2011). The promoter of the ferroportin gene contains HIF
response elements (HREs) that are targets for HIF2alpha bind-
ing, and mice lacking HIF2alpha, but not HIF1alpha, fail to upre-
gulate duodenal ferroportin mRNA in response to iron deficiency
(Taylor et al., 2011). Thus HIF2alpha has a demonstrable role in
increasing ferroportin transcription during hypoxia and iron
deficiency. Interestingly, HIF2alpha is also the predominant fac-
tor in the regulation of erythropoietin transcription, hinting at its
possible role as a coordinator between iron supply and erythro-
poiesis during the response to hypoxia.
At first glance, the IRP/IRE system in iron-deficient entero-
cytes would be expected to impair ferroportin expression
through translational repression by the 50 IRE of ferroportin.
The presence of a 50 IRE in Hif2alpha mRNA (Sanchez et al.,
2007) also raises the question of why the translation of Hif2alpha
mRNA is not repressed during enterocyte iron depletion.
Although such responses would protect enterocytes from
cellular iron deficiency, they would be detrimental to an iron-
deficient organism, as iron would be retained in enterocytes,
Figure 2. Ferroportin Regulation
Cellular iron efflux is proportional to the concen-
tration of ferroportin molecules on the membrane,
and multiple levels of ferroportin regulation exist in
different cell types.
(A) In iron-recycling macrophages, following eryth-
rophagocytosis both heme and iron increase ferro-
portin production. Heme regulates ferroportin tran-
scriptionally via the Bach1/Nrf2 complex (heme
causes degradation of repressor Bach1, resulting
in the stimulation of Fpn transcription by Nrf2).
Iron regulates ferroportin translationally through
modulating the interaction of IRPswith IREs in the 50
UTR of ferroportin (iron prevents IRPs from binding
to Fpn mRNA, allowing translation to proceed).
During infections with intracellular pathogens,
increased NO production leads to the activation
of Nrf2 and increased ferroportin transcription.
Inflammation can also suppress ferroportin tran-
scription through as-yet-unknown mechanisms.
Ferroportin is posttranslationally regulated by hep-
cidin-mediated endocytosis and proteolysis.
(B) In duodenal enterocytes, hypoxia induces fer-
roportin transcription via HIF2alpha. Retention of
iron in enterocytes during iron deficiency is avoi-
ded by the presence of ferroportin mRNAs that
lack 50 IRE. Hepcidin controls iron efflux from
enterocytes posttranslationallly by inducing the
endocytosis and proteolysis of ferroportin.
(C) Integration of diverse local and systemic in-
fluences on cellular iron efflux through ferroportin
regulation at the transcriptional, translational, and
posttranslational levels.
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clearly increases both ferroportin protein and mRNA expression.
The inability of the IRE/IRP system to repress ferroportin transla-
tion in duodenal enterocytes is explained only in part by the pres-
ence of a splicing variant of ferroportin mRNA, termed Fpn1b,
which lacks the 50 IRE but produces an identical protein (Zhang
et al., 2009). It appears that other, perhaps hypoxia-dependent,
mechanisms predominate to limit IRP1-mediated translational
repression (Anderson et al., 2013) and increase the concentra-
tions of HIF2alpha and the transcription and translation of ferro-
portin. Therefore, under conditions of iron deficiency, increased
production of ferroportin, combinedwith its decreased hepcidin-
mediated endocytosis and proteolysis, results in higher transfer
of iron from the diet into plasma at the expense of iron depletion
of enterocytes. Enterocytes are short-lived cells which are shed
into the intestinal lumen after a few days, so the organism may
tolerate their iron depletion. The relative timing and amplitude
of these complex iron- and hypoxia-sensitive elements in the fer-
roportin regulatory circuits have not yet been reported.
Interestingly, ferroportin lacking a 50 IRE (Fpn1b mRNA iso-
form) is also expressed by erythrocyte progenitor cells (Cianetti
et al., 2005; Zhang et al., 2009, 2011a). Under conditions of
iron limitation, Fpn1b would be continually translated, and this
may allow erythropoiesis to be ‘‘altruistic’’ and give up some of
its iron in order to increase supply to other tissues that require it.
In contrast to hypoxia and iron deficiency, inflammation de-
creases the expression of ferroportin, through effects on tran-
scription. This effect was initially observed in vivo for liver and
splenic Fpn1 mRNA as a consequence of inflammation caused
by administration of bacterial lipopolysaccharide (LPS), which
is a ligand for the innate immune sensor Toll-like receptor 4
(TLR4), (Liu et al., 2005a; Yang et al., 2002). Human monocyticcells were also shown to decrease FPN mRNA in response to
LPS and to interferon-gamma (Ludwiczek et al., 2003). The
mechanism of decreased Fpn mRNA caused by inflammation
is only partially understood. Suppression of Fpn1 mRNA by the
bacteria Pseudomonas aeruginosa requires intact TLR4 (Huang
et al., 2012; Peyssonnaux et al., 2006), whereas the Myco-
plasma-derived molecule FSL1 decreases Fpn1 in a TLR2-
dependent fashion (Guida et al., 2015); however, the decrease
of Fpn1 mRNA by LPS and the TLR3 ligand poly(I:C) do not
require the intracellular adaptors of TLR signaling, MyD88 or
TRIF (Huang et al., 2012). Even in the absence of hepcidin, these
mechanisms are sufficient to cause downregulation of duodenal
ferroportin (and DMT-1) by LPS (Deschemin and Vaulont, 2013)
and downregulation of splenic and liver ferroportin by FSL1
(Guida et al., 2015) leading to acute (3–6 hr after injection) hypo-
ferremia in mice. These results suggest that transcriptional
downregulation of ferroportin could contribute to the hypoferre-
mia of inflammation that can be protective against infection with
extracellular pathogens. However, the degree and duration of
hypoferremia caused by this inflammatory suppression of Fpn1
mRNA are relatively minor in the absence of hepcidin, as evi-
denced by the small effects on circulating iron after infection
with extracellular bacteria in hepcidin knockout mice (Arezes
et al., 2015).
Another layer of regulation of ferroportin activity arises from
macrophage differentiation and polarization. Macrophages are
markedly phenotypically and functionally diverse depending on
their source (yolk sac-derived precursors or circulating bone-
marrow derived monocytes), tissue location (resident in various
organs, or recruited from the blood), and exposure to a variety
of signals originating from other cells. Iron-recycling macro-
phages in the red pulp of the spleen, which express high levelsCell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 779
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development (Kohyama et al., 2009). SpiC activity is normally
repressed by Bach1; heme causes Bach1 degradation and
derepresses SpiC in monocytes, leading to their differentiation
into red pulp macrophages expressing ferroportin and heme-
oxygenase-1 (Haldar et al., 2014). Transcription of ferroportin
and heme-oxygenase-1 increases after heme-mediated Bach1
degradation and Nrf2 activation, as mentioned before. Thus,
increased levels of potentially toxic heme, for instance derived
from hemolytic events, drive both the development of the cell
type and the specific molecular processes that are equipped
to detoxify heme and recycle heme iron. However, macrophages
can also be differentiated in multiple other directions, simplified
as ranging from the M1 proinflammatory phenotype induced by
LPS or interferon-gamma to the M2 alternative specializations
characterized by anti-inflammatory and tissue remodeling func-
tion (Mosser and Edwards, 2008). In line with the transcriptional
stimulation of hepcidin by inflammatory signals, ferroportin
expression by M1 macrophages is low, and this, coupled with
increased ferritin levels, confers an iron sequestration phenotype
(Recalcati et al., 2010). However, macrophages exposed to
M-CSF, IL-4, or glucocorticoids assume an iron recycling/ex-
porting phenotype expressing hemoglobin processing machin-
ery, and high levels of ferroportin (Corna et al., 2010; Recalcati
et al., 2010; Sierra-Filardi et al., 2010; Vallelian et al., 2010).
As described in this section, ferroportin gene transcription and
translation are modulated by a number of multilayered signals.
However, the activity of the functional transporter on cell mem-
branes is predominantly governed posttranslationally by a sys-
temically acting peptide hormone, hepcidin (e.g., Laftah et al.,
2004; Rivera et al., 2005). Because hepcidin expression is itself
regulated by a complex integration of many physiological signals
including those arising from iron status, inflammation, and
erythroid drive (Ganz, 2013), hepcidin adds a crucial final layer
to the control of ferroportin activity (Figure 2C).
Ferroportin and Hepcidin
Hepcidin is a 25 amino acid peptide secreted into blood plasma
predominantly by hepatocytes. The sole well-documented phys-
iologic activity of hepcidin is its binding to ferroportin, which
results in ferroportin endocytosis and proteolysis, predominantly
in lysosomes (Nemeth et al., 2004). Accordingly, low hepcidin
states are characterized by high levels of ferroportin in iron-
transporting tissues and brisk iron export to extracellular fluid
and plasma. In contrast, high circulating hepcidin concentrations
cause ferroportin to disappear from cell membranes and iron
export to plasma to cease. The central importance of the hepci-
din-ferroportin interaction for iron homeostasis is highlighted by
the profound consequences of hepcidin deficiency or excess.
Complete genetic hepcidin deficiency causes the most severe
form of iron overload in mice (Lesbordes-Brion et al., 2006;
Nicolas et al., 2001) and humans (Roetto et al., 2003), and muta-
tions in ferroportin that prevent hepcidin binding (Altamura et al.,
2014) largely phenocopy hepcidin deficiency, with the exception
of iron-induced pancreatic injury, which for unclear reasons
causes premature mortality in the hepcidin-resistant homozy-
gous C326S ferroportin mouse. At the opposite extreme, trans-
genic overexpression of hepcidin results in lethal perinatal iron
deficiency (Nicolas et al., 2002), and the administration of syn-780 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.thetic hepcidin or its analogs to mice causes dose-dependent
hypoferremia (Rivera et al., 2005) and inhibits iron absorption
(Laftah et al., 2004), again indicating the dominant effect of hep-
cidin on the regulation of ferroportin function.
It has been reported that macrophage ferroportin may be
much more sensitive to the effect of hepcidin than ferroportin
on enterocytes (Chaston et al., 2008; Chung et al., 2009). In prin-
ciple, such organ-specific ferroportin responses to hepcidin
could result from differences in hepcidin binding, perhaps due
to organ-specific differences in ferroportin glycosylation (Can-
onne-Hergaux et al., 2006), possible differences in cellular endo-
cytic machinery (not specifically analyzed), or differential rates of
ferroportin synthesis, which strongly affects the net expression
of ferroportin on cell membranes. Definitive determination of
differences in ferroportin responses in the two organs may be
difficult. In vivo studies of radiolabelled hepcidin binding found
substantial binding both in the duodenum (proximal more than
distal) and in the spleen, where iron-recycling macrophages
are abundant (Rivera et al., 2005), but this technique cannot
detect small differences in receptor affinities. Despite any
possible quantitative differences, the phenotypes of major iron
disorders and of their animal models indicate that hepcidin ex-
erts a controlling influence on both duodenal enterocytes and re-
cycling macrophages: high hepcidin concentrations suppress
both intestinal iron absorption and macrophage iron recycling,
and conversely, hepcidin deficiency leads to both excessive
iron absorption and iron depletion of macrophages.
The structural determinants of the hepcidin-ferroportin inter-
action are partially understood. Ferroportin is a 12-transmem-
brane domain protein (Liu et al., 2005b) (Figure 3) belonging
to the major facilitator superfamily of transporters of small
molecules. Although technical obstacles caused some early
disagreement on this point, there is now consensus in the field
that both ferroportin termini are located on the cytoplasmic
side of the membrane (Liu et al., 2005b; Rice et al., 2009). The
thiol cysteine C326 is exposed to the extracellular milieu and is
essential for hepcidin binding, as demonstrated by the lack of ra-
diolabeled hepcidin binding by mutant ferroportins C326S and
C326T (Fernandes et al., 2009). The lack of hepcidin binding to
C326S ferroportin confers a gain-of-function phenotype in hu-
mans and in mice, resulting in early and severe iron overload
as a consequence of hyperabsorption of dietary iron (Altamura
et al., 2014; Sham et al., 2009). Extensive mutagenesis and mo-
lecular modeling identified the N-terminal 9 amino acids of the 25
amino acidmature hepcidin interactingwith the C326-containing
exofacial ferroportin segment, mainly through pi-stacking inter-
actions of aromatic side chains (Nemeth et al., 2006; Preza
et al., 2011a). The confidence in this model was reinforced by
the rational design of 9-amino acid minihepcidins that were as
potent as and more drug-like than hepcidin itself (Preza et al.,
2011b; Ramos et al., 2012).
It was reported that an unstructured 19 amino acid peptide
based on the C326-containing ferroportin loop acted as a spe-
cific binder of hepcidin and could be used for measurements
of hepcidin in plasma or urine (De Domenico et al., 2008). How-
ever, this claim could not be replicated in other laboratories, and
the publication was retracted, as it was found to have been
affected by research misconduct (paper #10 in the report by
McCormack et al., 2013).
Figure 3. Alternating Access Model of Iron Transport by Ferroportin
Ferroportin is a member of the major facilitator superfamily of transporters
which share a structural feature known as the MFS fold: 12 transmembrane
segments (TMs) organized into two six-helix halves, connected by a large
cytoplasmic loop between TM-6 and TM-7. Transport across the membrane
likely occurs via the alternate-access (rocker-switch) mechanism whereby the
two halves of the molecule cycle through inward-facing, occluded, and out-
ward-facing conformations to facilitate substrate transport. We hypothesize
(1) that ferrous iron binds to ferroportin in the open-in conformation; ferroportin
flips to the open-out conformation and releases ferrous iron to be oxidized by a
ferroxidase (Ferrox) and delivered to transferrin (Tf) in the ferric form; and (2)
that hepcidin binds to the open-out conformation, inducing a conformational
change that results in ubiquitination of the connecting loop and endocytosis of
ferroportin.
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tosis, the interaction of hepcidin with ferroportin could be ex-
pected to trigger a conformational change in ferroportin followed
by covalent modifications of one or more of its cytoplasmic seg-
ments to initiate endocytosis. Mutations that interfere with these
mechanisms would confer resistance to hepcidin. Several ferro-
portin mutations associated with partial resistance to hepcidin
(Drakesmith et al., 2005) affect amino acids located within the
cell membrane and do not prevent hepcidin binding (Fernandes
et al., 2009) but likely interfere with the conformational change
that is required to initiate endocytosis. Although the structural
details have not yet been elucidated, ferroportin endocytosis is
now known to depend on the hepcidin-induced ubiquitination
of multiple cytoplasmic lysines on the extended cytoplasmic
loop connecting the two halves of the ferroportin molecule
(Figure 3) (Qiao et al., 2012; Ross et al., 2012). The specific ubiq-
uitin ligases involved in the endocytosis of ferroportin remain to
be identified.
An earlier proposed mechanism claimed that hepcidin-in-
duced ferroportin endocytosis depended on JAK2-mediated
phosphorylation of ferroportin on a pair of cytoplasmic tyrosines
(Y302 and Y303) (De Domenico et al., 2007b, 2009). However,
these studies were subsequently contradicted (Ross et al.,
2012), and the articles were found to be affected by scientific
misconduct (papers #2 and #8 in the report by McCormack
et al., 2013). Contrary to the original claim that Y302F/Y303F
mutations confer resistance to hepcidin (De Domenico et al.,
2007b), these mutations were found to prevent ferroportin traf-
ficking to the membrane (Ross et al., 2012). Morover, Y302F/Y303F homozygosity in mice caused an embryonic lethal pheno-
type due to inadequate iron transfer across placenta (Altamura
et al., 2011), an opposite phenotype from that expected of hep-
cidin resistance. Concerns were also raised about the reported
key role of a single lysine residue K253 and the Nedd4-2 ligase
system in hepcidin-dependent and hepcidin-independent endo-
cytosis of ferroportin (De Domenico et al., 2011). The article was
confounded by misconduct (paper #1 in report by McCormack
et al., 2013) and was retracted.
Compared to most other cell types, macrophages are particu-
larly ferroportin-rich, especially in the spleen and the liver, where
they recycle iron from senescent erythrocytes. Macrophages
also have an important role as orchestrators of innate immunity,
in part by producing cytokines that modify the activity of cells
participating in host resistance to infection. Both functions of
macrophages, in iron homeostasis and in host defense, influ-
ence each other. Understanding the effects of iron on host re-
sistance has important implications for the treatment of iron
deficiency in settings where serious infections are endemic.
However, understanding of the effect of iron on macrophage
cytokine production has been complicated by the contradictory
findings in different studies. In mouse models, iron deficiency
and the resulting iron depletion ofmacrophages have been asso-
ciated with a heightened inflammatory response to LPS, which
could be prevented by hepcidin administration which promotes
macrophage iron retention (Pagani et al., 2011). However, in
HFE/ mice, where macrophages are also iron depleted and
hepcidin concentrations are also low, there was no difference
compared to WT mice in TNF-a and IL-6 plasma levels after
LPS stimulation (Roy et al., 2004). Furthermore, studies from iso-
lated macrophages demonstrated an opposite association be-
tween macrophage iron and cytokine production: iron depletion
via chelation reduced TNF-a and IL-6 secretion (Wang et al.,
2008), and iron accumulation in ferroportin-deficient macro-
phages potentiated TNF-a and IL-6 release compared to intact
macrophages (Zhang et al., 2011b). These apparently conflicting
conclusions from in vivo and in vitro experiments may be caused
by the heterogeneity of macrophage types, their differing expo-
sure to iron sources, and varying levels of ferroportin expression.
In principle, hepcidin could modulate cytokine secretion by
macrophages either through ferroportin-generated signaling or
by causing cytoplasmic iron retention and altering iron-depen-
dent intracellular signaling, including the hypoxia pathways
and the iron-regulatory protein pathways. One study proposed
that hepcidin triggered ferroportin signaling via JAK2-STAT3
pathway, causing anti-inflammatory transcriptional changes (De
Domenico et al., 2010). The study, however, was affected by
research misconduct (paper #3 in the report by McCormack
et al., 2013), and the involvement of JAK2-STAT3 was not
confirmed in subsequent studies (Ross et al., 2012). Thus both
the pathophysiology of iron effects on inflammation and the po-
tential mechanisms by which iron, hepcidin, and ferroportin
modulate inflammatory function of macrophages remain uncer-
tain (Table 1).
Mechanism of Iron Transport by Ferroportin and the
Role of Ferroxidases
Surprisingly little is known about how ferroportin transports iron.
Recent studies of the efflux of microinjected iron radioisotopesCell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 781
Table 1. Some Unanswered Questions about Ferroportin
What is the structure of ferroportin?
What is the molecular mechanism of iron transport?
How does hepcidin cause ferroportin endocytosis?
What is the molecular mechanism of ferroportin disease and its
autosomal dominance?
How does ferroportin-mediated iron export affect macrophage
immune functions?
What is the role of ferroportin in viral infection?
How does inflammation suppress ferroportin transcription?
What is the role of ferroportin in the heart, the erythroblast, the retina,
and the brain?
Does ferroportin have other organ-specific roles?
Is ferroportin activity coordinated with fluxes of other nutrients?
Cell Metabolism
Reviewfrom Xenopus oocytes established that this system should prove
useful for detailed analysis of iron transport by ferroportin (Mitch-
ell et al., 2014). Oocytes microinjected with ferroportin-GFP
mRNA express ferroportin on their membranes and export up
to 300 times more iron than control oocytes, and iron efflux is
strongly inhibited by the addition of hepcidin. The two common
iron forms Fe2+ and Fe3+ are readily interconverted, so definitive
determination of which species is transported by ferroportin is
challenging. Support for the transport of Fe2+ is provided by the
observation that the very similar cation Co2+ that is more stable
to oxidation under the usual experimental conditions is exported
from Xenopus oocytes with a similar rate constant as iron. More-
over, multiple experiments with the Xenopus oocyte system
found that iron effluxwas potentiated by apotransferrin (Donovan
et al., 2000; Mitchell et al., 2014) and ceruloplasmin (McKie et al.,
2000; Mitchell et al., 2014), the latter known as the principal fer-
roxidase in blood plasma that catalyzes the conversion of Fe2+
to Fe3+. This potentiating effect is ascribed to the increased con-
centration gradient for the release of Fe2+ from ferroportin, facil-
itating the movement of iron through the transporter.
All three known mammalian multicopper-containing ferroxi-
dases—ceruloplasmin, hephaestin, and zyklopen—oxidize Fe2+
to Fe3+, the form that is loaded onto plasma transferrin for
distribution to tissues. Ceruloplasmin and hephaestin have
been shown to facilitate cellular iron efflux in vivo, especially
in situations of increased demand for iron. In the duodenum, he-
phaestin is a transmembrane protein on enterocytes with an
extracellular domain that is highly homologous to theplasmapro-
tein ceruloplasmin. Ablation of hephaestin in mice results in mild
systemic iron deficiency andmild anemia, both of which improve
with age as iron demand for growth declines (Fuqua et al., 2014).
Systemic iron deficiencywas causedby decreased intestinal iron
absorption but was associated with excess iron retention within
enterocytes, indicative of impaired basolateral transport of iron
to plasma. The decrement in iron absorption occurred despite
an increased expression of ferroportin, demonstrating impaired
iron transport by ferroportin. Hephaestin is also found in thebrain,
where its ablation leads to age-dependent regional iron accumu-
lation (Jiang et al., 2015).
Ceruloplasmin is known in two forms, a blood plasma protein
and a GPI-linked membrane-associated protein, encoded by
splicing variants of the same gene. The GPI-linked ceruloplasmin
has been reported to be particularly abundant in the brain, where
it has a different distribution than hephaestin (Jiang et al., 2015).782 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.Patients and mouse models that lack ceruloplasmin accumulate
iron in the liver, the brain, and the retina, with resulting damage to
these organs. Ceruloplasmin-deficient humans and mice also
show signs of impaired iron mobilization from macrophages
and hepatocytes resulting in anemia (Harris et al., 1999; Osaki
and Johnson, 1969). During erythropoietic stress after bleeding,
ceruloplasminmay also facilitate augmented dietary iron transfer
to plasma (Cherukuri et al., 2005). Combined hephaestin-cerulo-
plasmin deficiency has particularly severe consequences in the
retina, where both proteins are expressed, causing a severe
form of macular degeneration (Hadziahmetovic et al., 2008). A
third ferroxidase, zyklopen, was described as a membrane pro-
tein highly expressed in the placenta (Chen et al., 2010), but its
physiological function has not yet been reported.
In view of the well-documented ability of the multicopper fer-
roxidases to influence ferroportin function, various modes by
which ferroxidases and ferroportin could interact have been
explored. In one model, GPI-linked ceruloplasmin (or an equiva-
lent sink for Fe2+) is required to remove Fe2+ from ferroportin in
astrocytes. In the absence of ceruloplasmin, Fe2+ becomes
‘‘stuck’’ in ferroportin, and this conformational state causes
astrocyte ferroportin to be ubiquitinated on K523 and to undergo
endocytosis and proteolysis (De Domenico et al., 2007a).
Although the hypothesis has some attractive features, including
the explanation of why aceruloplasminemia has such severe ef-
fects in the brain where soluble ceruloplasmin concentrations
are very low, the evidence for it is again confounded by miscon-
duct (paper #7 in the report by McCormack et al., 2013) and has
not yet been independently verified. Others have documented by
coimmunoprecipitation that hephaestin or GPI-ceruloplasmin
physically interacts with ferroportin (Jeong and David, 2003;
Yeh et al., 2009). Physical contact with a ferroxidase would
assure very low concentrations of Fe2+ on the exoface of ferro-
portin and could facilitate iron efflux.
Notmuch is knownabout themechanismbywhich intracellular
iron is delivered to ferroportin for export. A recent study (Yanatori
et al., 2014) reported that the iron chaperone protein PCBP2 (but
not its paralogue PCBP1) interacts with both DMT1 and ferropor-
tin. The results suggested that ferrous iron imported into the cyto-
plasm by DMT1 may be shuttled to ferroportin via PCBP2.
Fundamental questions about ferroportin, including its struc-
ture, the molecular mechanism of iron transport, the nature of
any symported or antiported species, and the mechanism by
which iron is delivered to ferroportin for export remain open for
investigation (Table 1).
Genetic Disorders of Ferroportin and Their Effects on
Systemic Iron Homeostasis
In the absence of definitive structural studies, important insights
into ferroportin structure emerged fromstudies of informative pa-
tients with iron disorders. Clinically detectable ferroportin muta-
tions are very heterogeneous, with a systematic review reporting
on 161 patients with 31 distinct mutations (Mayr et al., 2010).
They manifest a dominant pattern of inheritance and fall into
two broad phenotypic categories with some overlap. One group
ofmutations causes a ferroportin gain of function owing to partial
or complete resistance to hepcidin-induced ferroportin endocy-
tosis, as discussed in previous sections. The affected patients
hyperabsorb iron and present, often at a young age, with high
Cell Metabolism
Reviewtransferrin saturation, high plasma ferritin, and hepatic and other
organ iron overload with evidence of toxic damage. The pheno-
type resembles that of patients with classical hemochromatosis
from homozygous or compound heterozygous recessive muta-
tions in hepcidin or its regulators (HFE, TfR2, or hemojuvelin).
Another group of patients have dominant loss-of-function muta-
tions that cause high plasma ferritin but not high transferrin satu-
ration (a condition referred to as ‘‘ferroportin disease’’; Pietran-
gelo, 2004). These mutations appear to limit the rate of iron
export from recycling macrophages so that these macrophages
retain iron and as a consequence secrete high amounts of ferritin
into plasma (Cohen et al., 2010). Any loss of transport capacity
in the duodenum appears to be sufficiently compensated to
prevent systemic iron deficiency, unless the patients are phlebo-
tomized to remove accumulated iron. This disorder does not
appear to cause clinically important organ damage, presumably
because macrophages (unlike hepatocytes, cardiac myocytes,
or endocrine glandular tissue) are equipped to produce very large
amounts of reactive oxygen species during respiratory burst and
are therefore well defended against similar toxins generated
when they become iron overloaded. In principle, somemutations
could cause both decreased iron export and partial resistance to
hepcidin, and this could help explain the variable iron-loading
phenotypes in patients with the same mutation.
The ferroportin variant Q248H is common (a few percent) in
populations of African ancestry and has been weakly associated
with increased serum ferritin (Gordeuk et al., 2003; Kasvosve
et al., 2015; Rivers et al., 2007). The polymorphism may confer
a somewhat decreased sensitivity of ferroportin to hepcidin,
perhaps because of its proximity to cytoplasmic ubiquitination
sites involved in hepcidin-induced ferroportin endocytosis (Ne-
khai et al., 2013).
The puzzling feature of ferroportin disease is the structural ba-
sis of its mode of inheritance. Essentially all of the several dozen
reported mutations are heterozygous missense mutations that
act dominantly. This suggests that the ferroportin loss of function
is not due to haploinsufficiency, otherwise heterozygous non-
sense mutations or other gene defects that completely ablate
the production of protein from one of the alleles would also be
expected. At the functional level, the mutations cause either a
trafficking defect, so that insufficient ferroportin is displayed on
the cell membrane (Liu et al., 2005b; Schimanski et al., 2005),
or an iron transport defect that reduces the rate of iron efflux
per ferroportin molecule on the cell membrane (Liu et al.,
2005b; McGregor et al., 2005). There is evidence that some
mutations known to impair trafficking may also impair iron efflux
by membrane-associated ferroportin (McGregor et al., 2005).
Compared to the mouse model of haploinsufficiency (heterozy-
gous knockout) which had only a very mild form of macrophage
iron retention (Donovan et al., 2005), mice with ‘‘ferroportin dis-
ease’’ (flatiron mouse, H32R ferroportin mutation) showed age-
dependent accumulation of iron in hepatic macrophages and
relatively severe iron restriction, manifested by low transferrin
saturation and hypochromic erythrocytes on blood smears
(Zohn et al., 2007). Although the comparison was not made
side by side under the same conditions and identical strain back-
grounds, these findings are consistent with a dominant-negative
effect of the mutation. If ferroportin is transported to the mem-
brane in a multimeric form, a dominant-negative effect couldresult from missense mutations that cause mistrafficking of the
multimer. However, several dominant mutations (e.g., G323V,
N174I, G80S, R88G) were reported to cause deficient iron efflux
rather thanmistrafficking of ferroportin (Callebaut et al., 2014; De
Domenico et al., 2006; Liu et al., 2005b), and here the dominant-
negative effect may imply cooperativity between multiple ferro-
portin molecules engaged in iron transport. In such a model, a
transport-impaired ferroportin molecule would need to disrupt
the function of neighboring wild-type molecules.
Although the genetic evidence points to some kind of interac-
tion between ferroportin molecules that would cause a domi-
nant-negative effect, it has not been definitively determined
whether ferroportin is monomeric or multimeric during trafficking
or in thecellmembrane. This is inpartbecause themainpublished
evidence supporting the multimeric nature of ferroportin (De Do-
menico et al., 2007c) is clouded by scientific misconduct (paper
#9 in the report by McCormack et al., 2013). Several groups re-
ported evidence that ferroportin is a monomer, as determined
by a variety of methods (Gonc¸alves et al., 2006; Pignatti et al.,
2006; Schimanski et al., 2008), but others detected a dimeric
formcomplexedwith hephaestin (Yehet al., 2009). Detailedphys-
icochemical analysis of recombinant ferroportin extracted from
membranes (Riceet al., 2009) led to theconclusion that themono-
meric form is stable and functional, and binds hepcidin, but that
weak, detergent-sensitive homophilic interactions favoringmulti-
merization in thecellmembranecouldnotdefinitivelybe ruledout.
The Role of Ferroportin in Local Tissue Iron
Homeostasis and Its Disorders
In addition to its role as the sole cellular iron exporter in tissues
that provide iron for systemic needs (duodenum, iron-recycling
macrophages, hepatocytes, and placenta), there is increasing
evidence that ferroportin may also be involved in local iron ho-
meostasis. This function of ferroportin is best revealed by the
consequences of its tissue-specific ablation, as was done in car-
diac myocytes (Lakhal-Littleton et al., 2015), with resulting pro-
gressive impairment of the function of cardiomyocytes and the
premature death of the affected mice. These experiments raise
questions about the function of ferroportin in cells that do not
participate in systemic iron homeostasis. Is ferroportin func-
tioning as a safety valve to release iron generated during subcel-
lular remodeling (e.g., autophagy) or during uncontrolled uptake
in the course of transient episodes of complete transferrin satu-
ration with iron? Ferroportin in erythrocyte precursors (Zhang
et al., 2011a) may serve as such a safety valve that also makes
erythroblast iron available during periods of severe iron defi-
ciency to sustain vital organs at the expense of erythropoiesis.
An important role for ferroportin in the brain is presaged by the
adverse consequences of ceruloplasmin deficiency in mice and
humans, further exacerbated in mice when both hephaestin
and ceruloplasmin are ablated. It has also been suggested that
b-amyloid precursor protein (APP) may function as a ferroxidase
in neurons (Duce et al., 2010), implicating ferroportin in the path-
ogenesis of Alzheimer’s disease; however, the ferroxidase activ-
ity of APP turned out to be an artifact (Wong et al., 2014). This
does not exclude a role for APP in neuronal iron metabolism, as
the same authors providedmore evidence that APP can stabilize
ferroportin on the cell membrane and increase iron efflux by an
alternative and as-yet-undefinedmechanism (Wong et al., 2014).Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 783
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cation, have a particularly high requirement for iron. Recent
studies suggest that as cancer cells become more malignant,
they clonally evolve to retain iron by decreasing the expression
of ferroportin and increasing the secretion of hepcidin (Torti
and Torti, 2011). These characteristics are accompanied by an
increased pool of labile iron in cancer cells. Tumor-associated
macrophages appear to have an iron-exporting phenotype
which may provide iron to the cancer cells and further promote
tumor growth (Torti and Torti, 2011).
Ferroportin and Infection
Almost all infectious pathogens need to scavenge iron from the
host in order to multiply. The ferroportin/hepcidin axis controls
release of cellular iron frommacrophages into plasma, and there-
fore may play an important role in infections with microbes that
reside within macrophages or microbes that survive in
the bloodstream or other extracellular spaces (Drakesmith
and Prentice, 2012). Iron-dependent extracellular microbes are
exemplified by the pathogen Vibrio vulnificus, which causes rapid
death inmice lackinghepcidin.Hereunrestricted ferroportin activ-
ityprovidesampleextracellular iron (likely in the formof non-trans-
ferrin-bound iron), potentiating pathogen replication. Blockade of
ferroportin-mediated iron release into plasmaby administration of
minihepcidin peptides restored the ability of these mice to resist
Vibrio vulnificus and to survive the infection (Arezes et al., 2015).
Other work has concentrated on intracellular (macrophage-
tropic) pathogens in which ferroportin plays a different role. In
this context, iron release from infected cells into plasma could
be expected to deprive microbes of the iron they need to grow.
Consistent with this notion, increasing ferroportin expression by
retroviral gene transfer into cell lines in vitro decreasedmultiplica-
tion of Salmonella enterica serovar Typhimurium, and this effect
could be reversed by the addition of hepcidin (Chlosta et al.,
2006). In vivo, during the first few days of murine infection with
Salmonella enterica serovar Typhimurium, the stimulatory effect
of IL-6 on hepcidin production may lead to loss of ferroportin
from cell membranes, iron retention in macrophages, and stimu-
lation of intracellular growth (Kim et al., 2014). However, counter-
vailing effectsmay predominate during chronic infection:mecha-
nisms that increase ferroportin transcription appear as a part of a
natural and protective iron-modulating innate immune response
to Salmonella infection of macrophages, and this response can
be enhanced by interferon-gamma (Nairz et al., 2008). This
increased expression of ferroportin in macrophages is also
observed in vivo following infection of mice, where it results in
loss of spleen iron (Brown et al., 2015). The upregulation of ferro-
portin in Salmonella-infected macrophages is at least in part
driven by nitric-oxide-mediated Nrf2 activation, which in turn in-
creases transcription of the ferroportin gene (Nairz et al., 2013).
The interaction of other macrophage-tropic intracellular patho-
gens with ferroportin activity has been investigated. Ferroportin
overexpression was found to suppress the initial growth ofMyco-
bacterium tuberculosis in macrophage-like cell lines, although the
microbicidal activity of these cells was also compromised (John-
son et al., 2010). In the case of macrophage infection with Listeria
monocytogenes, wild-type bacteria that gain access to the
cytosol cause an upregulation of ferroportin (perhaps via nitric ox-
ide formation) which in turn limits iron availability to the pathogen;784 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.in contrast, L. monocytogenes lacking listeriolysin O, which is
required for bacteria to escape the phagolysosome and enter
the cytoplasm, do not increase ferroportin expression, and are
susceptible to iron-induced, ROS-mediated microbicidal activity
(Haschka et al., 2015).
Some pathogens may have evolved mechanisms for assuring
their intracellular iron supply. In addition to the early hypoferre-
mic and macrophage-iron-sequestering effect of Salmonella en-
terica serovar Typhimurium infection (Kim et al., 2014), it has also
been reported that macrophages infected with Leishmania ama-
zonensis decreased ferroportin expression in a TLR4- and hepci-
din-dependent manner (Ben-Othman et al., 2014). Furthermore,
replication of the parasite was enhanced by iron retention
caused by exogenously added hepcidin or by expression of
inactive ferroportin, whereas Leishmania growth was inhibited
by expression of a partially hepcidin-resistant ferroportin mutant
(N144H). In summary, ferroportin-mediated iron release from
macrophages can be a critical determinant for pathogen growth.
Enhanced ferroportin expression following Salmonella, Listeria,
Mycobacteria, and Leishmania infection is host protective in
each case, but it would appear that Salmonella (in acute in-
fection) and Leishmania may counteract this effect at least
temporarily and ensure their own iron supply by downregulating
ferroportin. Further work is required to elucidate the complex
time-dependent iron redistribution during in vivo infection with
various intracellular pathogens. Moreover, the specific role of
ferroportin in other infections that are known to interact with
iron homeostasis, for example the liver stage of Plasmodium
(Portugal et al., 2011), is not clear. Although in cell lines ferropor-
tin-mediated iron release inhibits replication of HIV-1 (Xu et al.,
2010), the interactions of hepcidin, ferroportin, and iron with viral
infections remain relatively unexplored.
Conclusions
Ferroportin is a unique iron exporter essential for dietary iron ab-
sorption, recycling of iron from senescent erythrocytes, mobili-
zation of stored iron, and iron transfer to the developing fetus.
It is the only known receptor for the iron-regulatory hormone
hepcidin, which binds to ferroportin, induces its endocytosis,
and thereby controls its membrane concentration and iron-ex-
porting activity. Especially inmacrophages, ferroportin synthesis
is regulated transcriptionally and translationally, presumably to
meet the rapidly changing requirements for iron export after er-
ythrophagocytosis and in response to macrophage infection by
intracellular microbes. The role of ferroportin in cellular iron ho-
meostasis, innate immunity, and cancer is becoming increas-
ingly recognized. Despite its importance, the structural basis of
ferroportin function and the mechanism by which ferroportin
transports iron are not understood.
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